VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
about
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialImmune checkpoint inhibitors: therapeutic advances in melanomaCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyRecent advances in understanding antitumor immunityIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsThe novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.Annexin A1 in primary tumors promotes melanoma dissemination.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.Immunotherapy for advanced melanoma: future directions.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.Programming the immune checkpoint to treat hematologic malignancies.Leprosy as a model to understand cancer immunosurveillance and T cell anergy.Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.New B7 Family Checkpoints in Human Cancers.Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulationVISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses.Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.Immune system and melanoma biology: a balance between immunosurveillance and immune escape.The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.Next generation immune-checkpoints for cancer therapy.Not All Immune Checkpoints Are Created EqualThe immunological synapse
P2860
Q26769884-13A6FC97-E13D-48C3-86E3-97EB016F7B91Q26775591-FAA7BC49-CF2A-474C-8187-571518C4DDFDQ28066199-67F24765-EAAB-4AEF-B624-49B0F602359BQ28067217-FE65C95B-9025-4F59-B4CF-3C0BCF525149Q28072532-4CA68CAB-9AD4-418D-9527-4AE0A8C5C22DQ33632116-F8C453F9-F55F-427D-9BE8-6C0A59103BD1Q34487653-137DDBA8-217B-4C85-A196-85198F1528C9Q36382143-AA3779A4-D318-4F6D-B2AC-96E2F91F99D2Q38305975-890296FF-4DA2-47CA-83E9-B856BB08D327Q38636569-955C6C4B-A774-4F46-9B2F-0007F28E7EABQ38710357-70881E6F-94EE-48A5-9088-2F71E1A7CE08Q38711163-4AFDD1FD-13C3-4226-91D0-739AE0370BFFQ38779877-566EEDF1-1400-418D-9BBC-78181D1D3000Q38796338-4B4F528E-66AD-4FCD-BCC8-378DBBC3A9BBQ38806070-245613FA-33C3-4815-B9EC-F9A531C58B1CQ38815454-FF2155AD-9D9E-4CEE-A7BC-49FC6728A9A7Q38996594-5534E026-F368-47D3-80BA-69942487C6A8Q39078341-965B05CD-0675-4D14-9DC2-3E09397F1910Q39416195-E58E691D-EC12-495C-A39C-53E9F8B016ACQ41382123-4D11A27F-6721-423F-86F0-798227021520Q41863599-44380E2F-1583-4DC8-8D0B-60EC54400ECFQ46971015-A966B1D2-024C-450A-94AD-350F7B9F1889Q47139628-D2D9CF08-DA95-4582-9C35-39103B647596Q47332473-2DD8F851-3500-461C-99EB-D1409DB7E5C2Q47936526-0D60F496-E0EB-4210-8C4B-1869684255EFQ48156081-A25D4F8F-3442-4C7A-BBDE-1F68264E2185Q48256829-D9B1E8FB-C98F-4FCF-8750-D48C21A9F7D5Q49166036-26B0584F-1C04-47E7-BD20-EC445ED5B54AQ49545290-595C789F-53F7-4FCA-83AE-B6DA825392C8Q52653710-D2F96F9F-7917-4D4B-B5F0-F2F9D5CA57CEQ52721812-E65583FF-7D84-4836-B089-83254D743C57Q52801913-24234007-29C7-4D1F-B421-521856A88815Q54960920-8223BBD7-715D-4603-89B0-5B086A08BC77Q55020853-BEADE6A5-7A54-4766-99DE-494896ABB7B1Q55060215-111BD21A-7832-4ACF-94CF-A8295BFCC272Q55383705-499DEAD1-B0EF-4F87-AFA6-345ABCE8CDA6Q56889626-8FA1BCCB-203D-4166-ABB2-751BE6051A2CQ57961866-F42CD795-BC20-4BA1-87FB-BEF9E831121A
P2860
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
@en
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
@nl
type
label
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
@en
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
@nl
prefLabel
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
@en
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
@nl
P2093
P2860
P1476
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
@en
P2093
J Louise Lines
Lorenzo F Sempere
Randolph Noelle
Thomas Broughton
P2860
P304
P356
10.1158/2326-6066.CIR-14-0072
P577
2014-06-01T00:00:00Z